Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review.

2.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Zeitoun G, Sissy CE, Kirilovsky A, Anitei G, Todosi AM, Marliot F, Haicheur N, Lagorce C, Berger A, Zinzindohoué F, Galon J, Scripcariu V, Pagès F.

Chirurgia (Bucur). 2019 Mar-Apr;114(2):152-161. doi: 10.21614/chirurgia.114.2.152.

3.

Automated exploration of Gene Ontology term and pathway networks with ClueGO-REST.

Mlecnik B, Galon J, Bindea G.

Bioinformatics. 2019 Mar 7. pii: btz163. doi: 10.1093/bioinformatics/btz163. [Epub ahead of print]

PMID:
30847467
4.

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Galon J, Bruni D.

Nat Rev Drug Discov. 2019 Mar;18(3):197-218. doi: 10.1038/s41573-018-0007-y. Review.

PMID:
30610226
5.

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.

Van den Eynde M, Mlecnik B, Bindea G, Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F, Angelova M, Vasaturo A, Bruni D, Jouret-Mourin A, Baldin P, Huyghe N, Haustermans K, Debucquoy A, Van Cutsem E, Gigot JF, Hubert C, Kartheuser A, Remue C, Léonard D, Valge-Archer V, Pagès F, Machiels JP, Galon J.

Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3. doi: 10.1016/j.ccell.2018.11.003.

PMID:
30537506
6.

Quantifying Immunoscore performance - Authors' reply.

Pagès F, Mlecnik B, Galon J.

Lancet. 2018 Nov 3;392(10158):1624-1625. doi: 10.1016/S0140-6736(18)32385-7. No abstract available.

PMID:
30496076
7.

Evolution of Metastases in Space and Time under Immune Selection.

Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, Hubert C, Kartheuser A, Humblet Y, Ceccarelli M, Syed N, Marincola FM, Bedognetti D, Van den Eynde M, Galon J.

Cell. 2018 Oct 18;175(3):751-765.e16. doi: 10.1016/j.cell.2018.09.018. Epub 2018 Oct 11.

PMID:
30318143
8.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

9.

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.

Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D.

Front Immunol. 2018 May 14;9:1044. doi: 10.3389/fimmu.2018.01044. eCollection 2018. Review.

10.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J.

Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.

PMID:
29754777
11.

Regulation of CTL Infiltration Within the Tumor Microenvironment.

Church SE, Galon J.

Adv Exp Med Biol. 2017;1036:33-49. doi: 10.1007/978-3-319-67577-0_3. Review.

PMID:
29275463
12.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

13.

World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016.

Galon J, Lugli A, Bifulco C, Pages F, Masucci G, Marincola FM, Ascierto PA.

J Transl Med. 2017 Oct 20;15(1):212. doi: 10.1186/s12967-017-1310-9.

14.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pagès F, Machiels JP, Galon J.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx123. Erratum in: J Natl Cancer Inst. 2018 Apr 1;110(4):438.

PMID:
28922789
15.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

16.

Comprehensive functional analysis of large lists of genes and proteins.

Mlecnik B, Galon J, Bindea G.

J Proteomics. 2018 Jan 16;171:2-10. doi: 10.1016/j.jprot.2017.03.016. Epub 2017 Mar 22.

PMID:
28343001
17.

[Focus on the Immunoscore and its potential clinical implications].

El Sissy C, Marliot F, Haicheur N, Kirilovsky A, Scripcariu D, Lagorce-Pagès C, Galon J, Pagès F.

Ann Pathol. 2017 Feb;37(1):29-38. doi: 10.1016/j.annpat.2016.12.010. Epub 2017 Feb 1. Review. French.

PMID:
28161000
18.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

19.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

20.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, Capone M.

J Transl Med. 2016 Sep 20;14:273. doi: 10.1186/s12967-016-1029-z.

21.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

22.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

23.

Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers.

Maby P, Galon J, Latouche JB.

Oncoimmunology. 2015 Nov 24;5(5):e1115943. doi: 10.1080/2162402X.2015.1115943. eCollection 2016 May.

24.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

J Immunother Cancer. 2016 Jun 21;4:37. doi: 10.1186/s40425-016-0142-0. eCollection 2016.

25.

Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification.

Ferris RL, Galon J.

J Natl Cancer Inst. 2016 May 12;108(8). pii: djw033. doi: 10.1093/jnci/djw033. Print 2016 Aug. No abstract available.

26.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Sep 2;5(3):e1088631. eCollection 2016 Mar. Review.

27.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F.

Int Immunol. 2016 Aug;28(8):373-82. doi: 10.1093/intimm/dxw021. Epub 2016 Apr 27. Review.

28.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

29.

Trial Watch-Immunostimulation with cytokines in cancer therapy.

Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1115942. eCollection 2016 Feb. Review.

30.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboüe R, Frebourg T, Pagès F, Valge-Archer V, Latouche JB, Galon J.

Immunity. 2016 Mar 15;44(3):698-711. doi: 10.1016/j.immuni.2016.02.025.

31.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

32.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M.

Oncoimmunology. 2015 Jun 9;5(1):e1057388. eCollection 2016.

33.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pagès F, Valge-Archer V, Galon J.

Sci Transl Med. 2016 Feb 24;8(327):327ra26. doi: 10.1126/scitranslmed.aad6352.

PMID:
26912905
34.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

35.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

36.

Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse.

Church SE, Galon J.

Immunity. 2015 Oct 20;43(4):631-3. doi: 10.1016/j.immuni.2015.10.004.

37.

Trial Watch: Adoptive cell transfer for oncological indications.

Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 May 5;4(11):e1046673. eCollection 2015 Nov. Review.

38.

From mice to humans: developments in cancer immunoediting.

Teng MW, Galon J, Fridman WH, Smyth MJ.

J Clin Invest. 2015 Sep;125(9):3338-46. doi: 10.1172/JCI80004. Epub 2015 Aug 4. Review.

39.

Trial watch: Naked and vectored DNA-based anticancer vaccines.

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Apr 2;4(5):e1026531. eCollection 2015 May.

40.

Trial Watch: Peptide-based anticancer vaccines.

Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Jan 9;4(4):e974411. eCollection 2015 Apr. Review.

41.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008866. eCollection 2015 Apr. Review.

42.

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008814. eCollection 2015 Apr. Review.

43.

Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.

Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, Angell HK, Fredriksen T, Elie N, Fauquembergue E, Drouet A, Leprince J, Benichou J, Mauillon J, Le Pessot F, Sesboüé R, Tuech JJ, Sabourin JC, Michel P, Frébourg T, Galon J, Latouche JB.

Cancer Res. 2015 Sep 1;75(17):3446-55. doi: 10.1158/0008-5472.CAN-14-3051. Epub 2015 Jun 9.

44.

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies.

Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G.

Oncotarget. 2015 May 20;6(14):11894-909.

45.

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Feb 3;4(1):e985940. eCollection 2015 Jan. Review.

46.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

47.

Trial Watch: Radioimmunotherapy for oncological indications.

Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e954929. eCollection 2014 Oct. Review.

48.

Trial watch: Dendritic cell-based anticancer therapy.

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 21;3(11):e963424. eCollection 2014 Nov. Review.

49.

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.

Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, Trajanoski Z.

Genome Biol. 2015 Mar 31;16:64. doi: 10.1186/s13059-015-0620-6.

50.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

Supplemental Content

Support Center